​

DexCom (DXCM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DXCM Stock Forecast

DexCom (DXCM) stock forecast, based on 52 Wall Street analysts, predicts a 12-month average price target of $84.55, with a high of $99.00 and a low of $71.00. This represents a 16.04% increase from the last price of $72.86.

$65 $80 $95 $110 $125 $140 High: $99 Avg: $84.55 Low: $71 Last Closed Price: $72.86

DXCM Stock Rating

DexCom stock's rating consensus is Buy, based on 52 Wall Street analysts. The breakdown includes 1 Strong Buy (1.92%), 41 Buy (78.85%), 8 Hold (15.38%), 2 Sell (3.85%), and 0 Strong Sell (0.00%).

Buy
Total 52 2 8 41 1 Strong Sell Sell Hold Buy Strong Buy

DXCM Price Target Upside V Benchmarks

TypeNameUpside
StockDexCom16.04%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks20.65%

Price Target Trends

1M3M12M
# Anlaysts21316
Avg Price Target$78.50$81.77$84.19
Last Closing Price$72.86$72.86$72.86
Upside/Downside7.74%12.23%15.55%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 265204--29
Dec, 254205--29
Nov, 254204--28
Oct, 254194--27
Sep, 253204--27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 12, 2026Barclays$71.00$69.671.91%-2.55%
Jan 09, 2026Bernstein$86.00$68.4325.68%18.03%
Dec 17, 2025Mizuho Securities$78.00$66.3717.52%7.05%
Dec 16, 2025Mike KratkyLeerink Partners$92.00$65.3840.72%26.27%
Dec 02, 2025Patrick WoodMorgan Stanley$75.00$63.5218.07%2.94%
Nov 10, 2025Morgan Stanley$63.00$55.2114.11%-13.53%
Nov 03, 2025Lee HambrightBernstein$84.00$58.2244.28%15.29%
Nov 03, 2025Barclays$80.00$58.2237.41%9.80%
Oct 31, 2025Matt O'BrienPiper Sandler$75.00$56.9731.65%2.94%
Oct 31, 2025RBC Capital$85.00$56.9549.25%16.66%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 12, 2026Morgan StanleyOverweightOverweighthold
Jan 12, 2026BarclaysEqual-WeightUnderweightdowngrade
Jan 09, 2026BernsteinOutperformOutperformhold
Dec 16, 2025Leerink PartnersOutperformOutperformhold
Dec 11, 2025CitigroupBuyBuyhold
Dec 02, 2025Morgan StanleyEqual-WeightOverweightupgrade
Nov 03, 2025BernsteinOutperformOutperformhold
Oct 31, 2025Piper SandlerBuyBuyhold
Oct 24, 2025Cowen & Co.BuyBuyhold
Oct 21, 2025Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.56$0.88$1.40-----
Avg Forecast$0.71$0.80$1.44$1.69$2.02$2.45$3.11$3.85
High Forecast$0.73$0.81$1.48$1.74$2.19$2.77$3.26$3.89
Low Forecast$0.69$0.78$1.40$1.60$1.79$2.01$2.95$3.82
Surprise %-21.13%10.00%-2.78%-----

Revenue Forecast

$2B $3B $4B $5B $6B $8B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.45B$2.91B$3.62B-----
Avg Forecast$2.45B$2.91B$3.60B$4.02B$4.61B$5.31B$6.26B$7.15B
High Forecast$2.50B$2.93B$3.63B$4.03B$4.65B$5.31B$6.30B$7.21B
Low Forecast$2.41B$2.87B$3.58B$4.00B$4.59B$5.30B$6.22B$7.11B
Surprise %-0.00%0.16%0.56%-----

Net Income Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$154.70M$341.20M$541.50M-----
Avg Forecast$108.96M$212.70M$541.50M$680.80M$779.93M$954.91M$1.32B$1.64B
High Forecast$140.14M$265.56M$676.08M$739.43M$931.55M$1.18B$1.39B$1.65B
Low Forecast$77.78M$159.84M$406.92M$679.93M$759.83M$856.02M$1.26B$1.63B
Surprise %41.98%60.41%------

DXCM Forecast FAQ

Is DexCom stock a buy?

DexCom stock has a consensus rating of Buy, based on 52 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 41 Buy, 8 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that DexCom is a favorable investment for most analysts.

What is DexCom's price target?

DexCom's price target, set by 52 Wall Street analysts, averages $84.55 over the next 12 months. The price target range spans from $71 at the low end to $99 at the high end, suggesting a potential 16.04% change from the previous closing price of $72.86.

How does DexCom stock forecast compare to its benchmarks?

DexCom's stock forecast shows a 16.04% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical device stocks industry (20.65%).

What is the breakdown of analyst ratings for DexCom over the past three months?

  • January 2026: 17.24% Strong Buy, 68.97% Buy, 13.79% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 13.79% Strong Buy, 68.97% Buy, 17.24% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is DexCom’s EPS forecast?

DexCom's average annual EPS forecast for its fiscal year ending in December 2024 is $1.69, marking a 20.71% increase from the reported $1.4 in 2023. Estimates for the following years are $2.02 in 2025, $2.45 in 2026, $3.11 in 2027, and $3.85 in 2028.

What is DexCom’s revenue forecast?

DexCom's average annual revenue forecast for its fiscal year ending in December 2024 is $4.02B, reflecting a 11.04% increase from the reported $3.62B in 2023. The forecast for 2025 is $4.61B, followed by $5.31B for 2026, $6.26B for 2027, and $7.15B for 2028.

What is DexCom’s net income forecast?

DexCom's net income forecast for the fiscal year ending in December 2024 stands at $680.8M, representing an 25.72% increase from the reported $541.5M in 2023. Projections indicate $779.93M in 2025, $954.91M in 2026, $1.32B in 2027, and $1.64B in 2028.